Literature DB >> 33382910

Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011).

Masatoshi Kudo1,2, Namiki Izumi1,3, Norihiro Kokudo1,4, Michiie Sakamoto1,5, Shuichiro Shiina1,6, Tadatoshi Takayama1,7, Ryosuke Tateishi1,8, Osamu Nakashima1,9, Takamichi Murakami1,10, Yutaka Matsuyama1,11, Arata Takahashi1,12,13, Hiroaki Miyata1,12,13, Shoji Kubo1,14.   

Abstract

In the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 22,134 new patients and 41,956 previously followed patients were compiled from 546 institutions over a 2-year period from 1 January 2010 to 31 December 2011. Basic statistics compiled for patients newly registered in the 21st survey were cause of death, medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 20th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy and with radiofrequency ablation. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 1998 and 2011 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment type (hepatectomy, local ablation therapy, transcatheter arterial chemoembolization, and hepatic arterial infusion chemotherapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2011 into four time-period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer.
© 2021 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.

Entities:  

Keywords:  Liver Cancer Study Group of Japan; combined hepatocellular cholangiocarcinoma; cumulative survival rate; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; nationwide follow-up survey

Year:  2021        PMID: 33382910     DOI: 10.1111/hepr.13612

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  4 in total

1.  Classification of hepatic venous tumor thrombus in hepatocellular carcinoma: should it describe tumor status or predict patient survival?

Authors:  Norihiro Kokudo; Wei Tang; Takashi Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

2.  Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.

Authors:  Jeong Il Yu; Wonseok Kang; Gyu Sang Yoo; Myung Ji Goh; Dong Hyun Sinn; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Jung Yong Hong; Ho Yeong Lim; Boram Park; Hee Chul Park
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

Review 3.  Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.

Authors:  Mina Komuta
Journal:  Clin Mol Hepatol       Date:  2022-01-14

Review 4.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.